PDCD1 and COVID-19: To date, very limited data are available addressing the clinical outcome of ICI-treated cancer patients also suffering from COVID-19 infection.74–77 The blockade of PD-1+ on CD8+ lymphocytes by ICI treatment might be reasonable in patients with COVID-19 in order to abrogate functional T cell exhaustion and restore vigorous T lymphocytic cytotoxicity against both the tumor and the viral antigens.